System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Vincent Sibaud is an expert in Dermatology at Oncopole Claudius Regaud (France). As of October 2026, ScienceLeadR ranks Vincent Sibaud in the top 1% of experts worldwide for Sexually Transmitted Diseases. Vincent Sibaud has authored 348 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 1 of them ongoing. SLR score: 1,210 (community average: 125). How the SLR is computed.

LeadR Profile

Vincent Sibaud Oncopole Claudius Regaud France
1 210 ScienceLeadR Reputation 1210

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Pharmacy - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Oncopole Claudius Regaud

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 348

Citations

Citations: 5 714 1st author: 50 Last author: 122 Unique author: 5

Main journals

Ann Dermatol Venereol 85
J Eur Acad Dermatol Venereol 29
Annales de Dermatologie et de Vénéréologie - FMC 19
Rev Med Interne 14
Annales de dermatologie et de vénéréologie, FMC 12

Best Journals

Ann Oncol 4
J Clin Oncol 2
Lancet Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.
PMID 42573454 — sexually transmitted diseases, dermatitis, neoplasms, skin diseases, therapeutics, psoriasis, dermatitis, atopic		J Eur Acad Dermatol Venereol20260
Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force "Dermatology for Cancer Patients".
PMID 42464053 — safety, neoplasms, immune checkpoint inhibitors, psoriasis, dermatology		Int J Dermatol20260
Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS).
PMID 42320407 — neoplasms, immune checkpoint inhibitors, myocarditis, myositis, myasthenia gravis		Eur J Cancer20260
Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.
PMID 42253044 — sexually transmitted diseases, fasciitis, melanoma, neoplasms, skin diseases, immune checkpoint inhibitors, therapeutics, pharmacovigilance, drug eruptions		J Eur Acad Dermatol Venereol20260
Optimized management of enfortumab vedotin-related dermatological toxicity.
PMID 42253089 — sexually transmitted diseases, glycoconjugates, skin diseases, drug eruptions		J Eur Acad Dermatol Venereol20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 2
N/A 1

By status:

Completed 1
Recruiting 1
Unknown 1

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis
NCT04227314 — stomatitis, aphthous, safety, tablets, stomatitis, therapeutics		Phase 3Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS